Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Immune Checkpoint Inhibitors (ICI)-Related Dermatitis 1COVID-19 1

Interventions

Hydroxychloroquine 4Standard of Care 2Sodium Chloride 2COH04S1 COVID-19 vaccine 2BNT162 Vaccine 2Azithromycin 2tocilizumab 1palbociclib 1ogalvibart 1monalizumab 1crexavibart 1cilgavimab and tixagevimab drug combination 1avdoralimab 1XAV-19 1Specimen Handling 1Radiotherapy 1Medical Marijuana 1Losartan 1Janus Kinase Inhibitors 1Ivermectin 1Interleukin-7 1HuMax-IL8 1Gelsolin 1CVnCoV COVID-19 vaccine 1COVID-19 Vaccines 12019-nCoV Vaccine mRNA-1273 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 11-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × COVID-19 × Janus Kinase Inhibitors × Clear all
NCT04404361 2024-06-05

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

CTI BioPharma

Phase 2 Terminated
200 enrolled 16 charts

COVID-19

Data powered by HemOnc (CC BY 4.0) Colophon âš¡